Torthaí cuardaigh - Hsiaowei Deng

  • 1 - 8 toradh as 8 á dtaispeáint
Beachtaigh na torthaí
  1. 1
    123I-<i>Meta</i>-Iodobenzylguanidine Scintigraphy for the Detection of Neuroblastoma and Pheochromocytoma: Results of a Meta-Analysis

    123I-<i>Meta</i>-Iodobenzylguanidine Scintigraphy for the Detection of Neuroblastoma and Pheochromocytoma: Results of a Meta-Analysis de réir Arnold Jacobson, Hsiaowei Deng, John Lombard, Harry J. Lessig, Richard R. Black

    Foilsithe / Cruthaithe 2010
    Faigh an téacs iomlán
    Revisão
    Cuir le mo chuid Ceanán
    Sábháilte in:
  2. 2
    Canagliflozin and renal outcomes in type 2 diabetes: results from the CANVAS Program randomised clinical trials

    Canagliflozin and renal outcomes in type 2 diabetes: results from the CANVAS Program randomised clinical trials de réir Vlado Perkovic, Dick de Zeeuw, Kenneth W. Mahaffey, Greg Fulcher, Ngozi Erondu, Wayne Shaw, Terrance D. Barrett, Michele A. Weidner‐Wells, Hsiaowei Deng, David R. Matthews, Bruce Neal

    Foilsithe / Cruthaithe 2018
    Faigh an téacs iomlán
    Artigo
    Cuir le mo chuid Ceanán
    Sábháilte in:
  3. 3
    Rationale, design and baseline characteristics of the CANagliflozin cardioVascular Assessment Study–Renal (<scp>CANVAS‐R</scp>): A randomized, placebo‐controlled trial

    Rationale, design and baseline characteristics of the CANagliflozin cardioVascular Assessment Study–Renal (<scp>CANVAS‐R</scp>): A randomized, placebo‐controlled trial de réir Bruce Neal, Vlado Perkovic, David R. Matthews, Kenneth W. Mahaffey, Greg Fulcher, Gary Meininger, Ngozi Erondu, Mehul Desai, Wayne Shaw, Frank Vercruysse, Jacqueline Yee, Hsiaowei Deng, Dick de Zeeuw

    Foilsithe / Cruthaithe 2017
    Faigh an téacs iomlán Faigh an téacs iomlán
    Artigo
    Cuir le mo chuid Ceanán
    Sábháilte in:
  4. 4
    Cardiovascular and Renal Outcomes With Canagliflozin According to Baseline Kidney Function

    Cardiovascular and Renal Outcomes With Canagliflozin According to Baseline Kidney Function de réir Brendon L. Neuen, Toshiaki Ohkuma, Bruce Neal, David R. Matthews, Dick de Zeeuw, Kenneth W. Mahaffey, Greg Fulcher, Mehul Desai, Qiang Li, Hsiaowei Deng, Norm Rosenthal, Meg Jardine, George L. Bakris, Vlado Perkovic

    Foilsithe / Cruthaithe 2018
    Faigh an téacs iomlán
    Artigo
    Cuir le mo chuid Ceanán
    Sábháilte in:
  5. 5
    A comprehensive analysis of the effects of rivaroxaban on stroke or transient ischaemic attack in patients with heart failure, coronary artery disease, and sinus rhythm: the COMMANDER HF trial

    A comprehensive analysis of the effects of rivaroxaban on stroke or transient ischaemic attack in patients with heart failure, coronary artery disease, and sinus rhythm: the COMMAN... de réir Mandeep R. Mehra, Muthiah Vaduganathan, Min Fu, João Pedro Ferreira, Stefan D. Anker, John G.F. Cleland, Carolyn S.P. Lam, Dirk J. van Veldhuisen, William M. Byra, Theodore E. Spiro, Hsiaowei Deng, Faı̈ez Zannad, Barry Greenberg

    Foilsithe / Cruthaithe 2019
    Faigh an téacs iomlán Faigh an téacs iomlán
    Artigo
    Cuir le mo chuid Ceanán
    Sábháilte in:
  6. 6
    Natriuretic Peptide-Based Inclusion Criteria in a Heart Failure Clinical Trial

    Natriuretic Peptide-Based Inclusion Criteria in a Heart Failure Clinical Trial de réir Jonathan W. Cunningham, João Pedro Ferreira, Hsiaowei Deng, Stefan D. Anker, William M. Byra, John G.F. Cleland, Mihai Gheorghiade, Carolyn S.P. Lam, David La Police, Mandeep R. Mehra, James D. Neaton, Theodore E. Spiro, Dirk J. van Veldhuisen, Barry Greenberg, Faı̈ez Zannad

    Foilsithe / Cruthaithe 2020
    Faigh an téacs iomlán
    Artigo
    Cuir le mo chuid Ceanán
    Sábháilte in:
  7. 7
    Association of Rivaroxaban With Thromboembolic Events in Patients With Heart Failure, Coronary Disease, and Sinus Rhythm

    Association of Rivaroxaban With Thromboembolic Events in Patients With Heart Failure, Coronary Disease, and Sinus Rhythm de réir Barry Greenberg, James D. Neaton, Stefan D. Anker, William M. Byra, John G.F. Cleland, Hsiaowei Deng, Min Fu, David A. La Police, Carolyn S.P. Lam, Mandeep R. Mehra, Christopher C. Nessel, Theodore E. Spiro, Dirk J. van Veldhuisen, Catherine M. Vanden Boom, Faı̈ez Zannad

    Foilsithe / Cruthaithe 2019
    Faigh an téacs iomlán Faigh an téacs iomlán
    Artigo
    Cuir le mo chuid Ceanán
    Sábháilte in:
  8. 8
    Oral Factor XIa Inhibitor Milvexian After a Recent Acute Coronary Syndrome: Rationale and Design of the Phase 3 (Librexia ACS)

    Oral Factor XIa Inhibitor Milvexian After a Recent Acute Coronary Syndrome: Rationale and Design of the Phase 3 (Librexia ACS) de réir C. Michael Gibson, Maria Cecilia Bahit, Roxana Mehran, Shamir R Mehta, Rasha Al Lamee, Shinya Goto, Jeffrey I. Weitz, Jay Horrow, Elliot S. Barnathan, Robert A. Harrington, Kenneth W. Mahaffey, Siniša Car, Karen S. Pieper, S. Claiborne Johnston, Graeme J. Hankey, Alexei N. Plotnikov, Danshi Li, Hsiaowei Deng, Philippe Gabríel Steg

    Foilsithe / Cruthaithe 2025
    Faigh an téacs iomlán
    Artigo
    Cuir le mo chuid Ceanán
    Sábháilte in:

Uirlisí cuardaigh: